Dualitas Therapeutics

Dualitas Therapeutics announced a leadership change on June 8, 2026. Dualitas Therapeutics appointed Karim Dabbagh, formerly President and CEO of Silver Creek Pharmaceuticals, as Chief Executive Officer, with former interim CEO Rich Murray remaining on the Board of Directors.

What changed

Karim Dabbagh was named Chief Executive Officer. Rich Murray, who served as interim CEO from January 2025, will remain on the Board of Directors.

• Leader: Karim Dabbagh
• Role: Chief Executive Officer
• Effective: Not specified in the announcement
• Announcement date: June 8, 2026

Leadership background

Dabbagh was previously President and CEO of Silver Creek Pharmaceuticals and has more than two decades of biotech and pharma leadership experience, specializing in immunology and inflammation. He also served as President and CEO of Second Genome, where he helped build the company’s R&D platform and secured collaborations with Gilead Sciences and Bayer. He previously led Pfizer’s immunoregulation department and held leadership roles in Inflammation Discovery Research at Roche.

The mandate

Dualitas said Dabbagh will lead the company as it advances its lead development candidate, DTX-102, for autoimmune indications including rheumatoid arthritis. The company said IND-enabling studies have begun for DTX-102 and that it is anticipated to enter the clinic in 2027.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: Dualitas Therapeutics leadership announcement.